For five years, billionaire Mark Cuban has focused on reducing costs for generic medications, including chemotherapy agents and antifungal ointments, making them more affordable for American patients. Earlier this year, a new category of medicine arrived at his Dallas facility, signaling a strategic shift.
Among the initial shipments were DNA-inspired molecules synthesized by California chemists designed to correct a rare genetic mutation ravaging a single patient’s neurons. Another batch, developed in collaboration with Dutch researchers, targeted a progressive muscle-wasting disorder affecting adults.
These shipments mark the inaugural test of Cuban’s expanded vision for Cost Plus Drugs, aiming to disrupt the custom rare disease medicine landscape. In an email, Cuban noted, ‘It was an obvious chance for us to help those in that unfortunate situation.’
Also Read
- Iowa Medicare Plan Cancellations Affect More Than 87,000, Leaving Mayo Clinic Without In-Network Option
- Employer-Sponsored Health Insurance Costs Surge, Placing Greater Financial Burden on Workers
- Expectation Over Sensation: How Unblinding Undermines Placebo Effects in Pain Research
- How a Fake Side Effect Made a Placebo Painkiller More Effective
